Related Experiment Videos
Ventricular remodeling: from bedside to molecule
R Jaffe1, M Y Flugelman, D A Halon
1Department of Cardiology, Lady Davis Carmel Medical Center, Haifa, Israel.
Insights
Heart failure results from maladaptive hypertrophy, cell death, and vascular changes, driven by complex molecular and genetic factors. Understanding these mechanisms is key to developing new treatments for ventricular remodeling.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- Pathophysiology of Heart Failure
Background:
- Myocardial remodeling is a complex process involving hypertrophy, ventricular dilatation, and heart failure.
- The decompensation of hypertrophic remodeled myocardium involves synergistic mechanisms that are not fully understood.
Purpose of the Study:
- To explore the molecular and genetic mechanisms underlying maladaptive hypertrophy and heart failure.
- To identify key factors contributing to ventricular remodeling and decompensation.
Main Methods:
- Analysis of myocardial gene expression.
- Investigation of neurohormonal systems (e.g., renin-angiotensin).
- Assessment of interstitial matrix composition and immune system components (e.g., TNF-alpha).
Main Results:
- Maladaptive hypertrophy (abnormal myosin-actin production) contributes to progressive ventricular dilatation.
- Programmed cell death (apoptosis) and changes in interstitial vasculature/collagen impact heart function.
- Molecular factors include altered gene expression, activated neurohormonal systems, increased matrix metalloproteinase activity, and TNF-alpha expression.
Conclusions:
- The decompensation of hypertrophic remodeled myocardium is multifactorial, involving maladaptive hypertrophy, apoptosis, and interstitial changes.
- Understanding these molecular and genetic pathways is crucial for developing targeted therapies.
- Future research aims to improve interventions for ventricular remodeling and heart failure.
Abstract:
The multiple mechanisms that bring about the decompensation of the hypertrophic remodeled myocardium are synergistic and not fully understood. Our current hypothesis is that the increased stress on the ventricle is initially offset by compensatory myocardial hypertrophy. In many instances, however, progressive ventricular dilatation and heart failure occur as a result of maladaptive hypertrophy (abnormal myosin-actin production), programmed cell death (apoptosis) and/or changes in the interstitial vasculature and collagen composition. The molecular and genetic background to these processes includes changes in myocardial gene expression, activation of the local tissue renin-angiotensin and other neurohormonal systems, increased matrix metalloproteinase activity (including collagenase), and expression of certain components of the immune system, such as TNF-alpha. Future research will hopefully provide better methods for limiting the remodeling-ventricular dilatation process by novel pharmacotherapies, gene therapy and, possibly, surgical therapy, and determine the impact of such interventions on survival.